Other substances

Hesperidin

A disaccharide derivative and a dihydroxyflavanone.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Hesperidin on PubChem

C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Evaluation of Flavonoids as 2019-nCoV Cell Entry Inhibitor Through Molecular Docking and Pharmacological Analysis Preprint In silico	in silico			Apr/06/2020
Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors ACE2 RNA TMPRSS2 Small molecule In silico	in silico	2.11	Predicted to bind human ACE2, GRP78, AT1R, and TMPRSS2 receptors.	Aug/07/2020
Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV-2 3CLpro Small molecule In silico	in silico	2.08	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Aug/18/2020
Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins Small molecule In silico	in silico	3.22	Predicted to bind to multiple SARS-CoV-2 viral proteins.	Oct/27/2020
Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations 3CLpro RdRpol Small molecule In silico	in silico	3.22	Predicted to bind the SARS-CoV-2 RNA-dependent RNA polymerase and the 3C-like protease.	Oct/21/2020
Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2 Spike protein ACE2 Small molecule In silico	in silico	4.00	Predicted to bind the host ACE2 receptor (introducing a conformational change) and also ACE2 in complex with the spike protein of SARS-CoV-2.	Oct/19/2020

AI-suggested references

Link	Publication date
Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections.	Jan/19/2021
Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2.	Dec/01/2021
Exploring the Potential Pharmacological Mechanism of Hesperidin and Glucosyl Hesperidin against COVID-19 Based on Bioinformatics Analyses and Antiviral Assays.	Mar/02/2022
Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study.	Dec/23/2020
In silico study of potential anti-SARS cell entry phytoligands from Phlomis aurea: a promising avenue for prophylaxis	Mar/24/2022
Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19.	Sep/09/2020
A Review of Medicinal Plants with Antiviral Activity Available in Bangladesh and Mechanistic Insight Into Their Bioactive Metabolites on SARS-CoV-2, HIV and HBV.	Nov/08/2021
Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus	May/25/2020
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study	May/13/2020
Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2.	Jun/15/2021
Exploring the inhibitory potential of Saussurea costus and Saussurea involucrata phytoconstituents against the Spike glycoprotein receptor binding domain of SARS-CoV-2 Delta (B.1.617.2) variant and the main protease (Mpro) as therapeutic candidates, using	Apr/09/2022
Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19	Oct/29/2022
Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury.	Jan/27/2021
Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis	Jul/28/2020
Drug repurposing using computational methods to identify therapeutic options for COVID-19	May/30/2020
Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease	Mar/08/2021
A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle	Jul/05/2020
Flavonoids as Promising Antiviral Agents against SARS-CoV-2 Infection: A Mechanistic Review	Apr/08/2022
Molecular docking and dynamics studies on propolis sulabiroin-A as a potential inhibitor of SARS-CoV-2.	Nov/15/2021
Antiviral zinc oxide nanoparticles mediated by hesperidin and in silico comparison study between antiviral phenolics as anti-SARS-CoV-2.	Mar/26/2021
Network-Based Identification and Experimental Validation of Drug Candidates Toward SARS-CoV-2 via Targeting Virus-Host Interactome	Oct/25/2021
Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (Mpro) of SARS-CoV-2	Feb/28/2021
In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.	Oct/29/2020
Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico Screening.	Jul/20/2021
Citrus fruits are rich in flavonoids for immunoregulation and potential targeting ACE2	Feb/14/2022
In silico identification of SARS-CoV-2 spike (S) protein-ACE2 complex inhibitors from eight Tecoma species and cultivars analyzed by LC-MS	May/22/2021
In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis	Jan/31/2022
Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of "Different Diseases with the Same Treatment" Based on Network Pharmacology	May/25/2021
Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection	May/08/2020
A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2	Oct/13/2020
Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2	Mar/29/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04452799	Hesperidin and Diosmin for Treatment of COVID-19	Not yet recruiting	Early Phase 1	Jul/01/2020	Oct/30/2020
Alternative id - 1111 Interventions - Drug: Hesperidin and Diosmin mixture Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Care Provider)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - PCR test\|respiratory rate\|patients PaO2\|serum IL1β\|serum TNF-α\|Mortality rate
NCT04715932	Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)	Completed	Phase 2	Feb/18/2021	Jun/07/2021
Alternative id - MHICC-2020-003 Interventions - Drug: Hesperidin\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Montreal Heart Institute, Montréal, Quebec, Canada Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 216 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of subjects with COVID-19 symptoms.\|Mean number of COVID-19 symptoms.\|Duration of COVID-19 symptoms.\|For each COVID-19 symptom listed in the appendix, proportion of subjects with the symptom.

Export (.csv)